Subscribe To

Price Alert Latest News Economic Calendar News

ACIU / AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals

Shares of biotech AC Immune SA ACIU, -9.21% slid 15% in premarket trade Thursday, after the company said a a trial of a treatment for Alzheimer's disease failed to slow or prevent cognitive decline in patients with a specific genetic mutation that causes early-onset disease. The trial involved 252 people who are members of the world's biggest extended family with Autosomal Dominant Alzheimer's Disease, or ADAD, in Colombia. Read More

Demo Live Account See Partner Details

Content Topics

Immune

Slide

Premarket

After

Trial

Alzheimer

Alzheimer s

Treatment

Misses

Stock

ACIU

Posted: Jun 16 2022, 06:39

Author Name: Market Watch

ACIU News

By Zacks Investment Research
October 24, 2023

Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?

Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

By Zacks Investment Research
October 20, 2023

AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the k

By Zacks Investment Research
September 5, 2023

AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why

AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for

By GlobeNewsWire
September 5, 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

By Zacks Investment Research
August 4, 2023

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

AC Immune (ACIU) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share

By The Motley Fool
June 30, 2023

Why Shares of AC Immune Jumped This Week

AC Immune is a clinical-stage biotech with 16 programs in its pipeline. It is attempting to develop an Alzheimer's disease vaccine.

By PennyStocks
June 28, 2023

Trading Penny Stocks With Limited Capital: 3 Tops Tips

The allure of penny stocks is undeniable. Their low price and potential for massive returns create an inviting landscape for individuals, especially t

By Market Watch
June 27, 2023

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

AC Immune SA's stock ACIU, +4.21% soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration f

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.